This site is intended only for healthcare professionals resident in the Republic of Ireland




Sign in or registerLog out Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up
PortfolioSupport & ResourcesPatient support 




Ngenla®▼ (Somatrogon Injection) the once-weekly growth hormone (GH) for the treatment of children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone.1

Learn More Loading

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.  Healthcare professionals are asked to report any suspected adverse reactions. Refer to section 4.8 of the SPC for how to report adverse reactions.

Genotropin for Growth Hormone Deficiency

Genotropin is a growth hormone therapy indicated for the treatment of growth disturbance in children due to insufficient secretion of growth hormone (growth hormone deficiency, GHD) and growth disturbance associated with Turner Syndrome or chronic renal insufficiency (CRI) or growth disturbance in short children born small for gestational age (SGA) with a birth weight and/or length below –2SD, who failed to show catch-up growth by 4 years of age or later.2

View Genotropin® SmPC Loading
Somavert for the Treatment of Acromegaly

Somavert is used in the treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise IGF-1 concentrations or was not tolerated.3

View Somavert® SmPC Loading

Prescribing Information:

Somavert Prescribing Information

Genotropin Prescribing Information

Ngenla Prescribing Information

References:NGENLA® Summary of Product CharacteristicsGenotropin Summary of Product CharacteristicsSomavert Summary of Product Characteristics
Support & Resources

Learn more about patient resources available to support your patients.

Find out more Loading

Legal Category: S1A
Further information is available upon request

PP-GEN-IRL-0320 December 2022

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit


This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.


Copyright © 2023 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0176. January 2023
For Healthcare Professionals in the Republic of Ireland *

The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.

I confirm that I am a healthcare professional resident in the Republic of Ireland.*

I accept and agree to the terms of use.*

If you select 'No', you will be redirected to, where you will be able to access information on Pfizer Healthcare Ireland.

PP-UNP-IRL-0176. January 2023

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.